Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;28(6):277–280. doi: 10.1002/clc.4960280604

Clinical update: The role of angiotensin II receptor blockers in patients with left ventricular dysfunction (Part II of II)

T Barry Levine 1,✉, Arlene B Levine 1
PMCID: PMC6654260  PMID: 16028461

Abstract

Almost 5 million individuals in the United States have chronic heart failure (HF), which is increasing in prevalence. Angiotensin‐converting enzyme (ACE) inhibitors are standard therapies for HF, although more than 10% of patients with HF are unable to tolerate these agents. Furthermore, ACE inhibitors may not provide complete blockade of the renin‐angiotensin system (RAS) in the long term. Because angiotensin II receptor blockers (ARBs) may block the RAS more completely than ACE inhibitors and are better tolerated, several large‐scale ARB trials have been performed exploring their potential role in treating patients with symptomatic HF and left ventricular systolic dysfunction. The Losartan Heart Failure Survival Study (ELITE II) demonstrated no significant differences in morbidity and mortality between the ARB losartan and the ACE inhibitor captopril among elderly patients with HF. The Valsartan Heart Failure Trial (Val‐HeFT) demonstrated reductions in hospitalizations for HF with the ARB valsartan when added to standard HF therapy, with no effect on mortality. Both trials suggested a potential negative interaction between ARB and beta‐blocker therapy. The Candesartan in Heart failure‐Assessment of Reduction in Mortality and morbidity (CHARM) program demonstrated significant reductions in morbidity and mortality with the ARB candesartan in patients withHF due to systolic dysfunction, with or without ACE inhibitors and with or without beta blockers. Thus, the addition of ARBs to the treatment regimen of patients with symptomatic HF should be strongly considered.

Keywords: heart failure, angiotensin‐converting enzyme inhibitors, angiotensin II receptor blockers

Full Text

The Full Text of this article is available as a PDF (45.8 KB).

References

  • 1. American Heart Association : Heart Disease and Stroke Statistics‐2004 Update. Dallas, Tex: American Heart Association, 2003. [Google Scholar]
  • 2. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, and the American College of Cardiology/American Heart Association : ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38 (7): 2101–2113 [DOI] [PubMed] [Google Scholar]
  • 3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KKL, Murabito JM, Vasan RS: Long‐term trends in the incidence of and survival withheart failure. N Engl J Med 2002; 347 (18): 1397–1402 [DOI] [PubMed] [Google Scholar]
  • 4. Roger VL, Weston SA, Redfield MM, Hellermann‐Homan JP, Killian J, Yawn BP, Jacobsen SJ: Trends in heart failure incidence and survival in a community‐based population. J Am Med Assoc 2004; 292 (3): 344–350 [DOI] [PubMed] [Google Scholar]
  • 5. Bart BA, Ertl G, Held P, Kuch J, Maggioni AP, McMurray J, Michelson EL, Rouleau JL, Stevenson LW, Swedberg K, Young JB, Yusuf S, Sellers MA, Granger CB, Califf RM, Pfeffer MA, for the SPICE investigators : Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999; 20 (16): 1182–1190 [DOI] [PubMed] [Google Scholar]
  • 6. Roig E, Perez‐Villa F, Morales M, Jiménez W Orús J, Heras M, Sanz G: Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21 (1): 53–57 [DOI] [PubMed] [Google Scholar]
  • 7. Wolny A, Clozel J‐P, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W: Functional and biochemical analysis of angiotensin II‐forming pathways in the human heart. Circ Res 1997; 80 (2): 219–227 [DOI] [PubMed] [Google Scholar]
  • 8. Pitt B, Poole‐Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B, on behalf of the ELITE II Investigators : Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355 (9215): 1582–1587 [DOI] [PubMed] [Google Scholar]
  • 9. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators : A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345 (23): 1667–1675 [DOI] [PubMed] [Google Scholar]
  • 10. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Östergren J, Yusuf S, and the CHARM Investigators and Committees : Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM‐Overall programme. Lancet 2003; 362 (9386): 759–766 [DOI] [PubMed] [Google Scholar]
  • 11. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Östergren J, Pfeffer MA, Swedberg K, and the CHARM Investigators and Committees : Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function intolerant to angiotensin‐converting‐enzyme inhibitors: The CHARM‐Alternative trial. Lancet 2003; 362 (9386): 772–776 [DOI] [PubMed] [Google Scholar]
  • 12. The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325 (5): 293–302 [DOI] [PubMed] [Google Scholar]
  • 13. McMurray JJV, Östergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, for the CHARM Investigators and Committees : Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function taking angiotensin‐converting‐enzyme inhibitors: The CHARM‐Added trial. Lancet 2003; 362 (9386): 767–771 [DOI] [PubMed] [Google Scholar]
  • 14. Chung O, Csikós T, Unger T: Angiotensin II receptor pharmacology and AT1‐receptor blockers. J Hum Hypertens 1999; 13 (suppl 1): S11–S20 [DOI] [PubMed] [Google Scholar]
  • 15. Morsing P, Adler G, Brandt‐Eliasson U, Karp L, Ohlson K, Renberg L, Sjöquist P‐O, Abrahamsson T: Mechanistic differences of various AT1‐receptor blockers in isolated vessels of different origin. Hypertension 1999; 33 (6): 1406–1413 [DOI] [PubMed] [Google Scholar]
  • 16. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J: Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3 (5): 283–291, 318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B: An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7 (2): 135–142 [DOI] [PubMed] [Google Scholar]
  • 18. Elmfeldt D, Olofsson B, Meredith P: The relationships between dose and antihypertensive effect of four AT1‐receptor blockers. Differences in potency and efficacy. Blood Press 2002; 11 (5): 293–301 [DOI] [PubMed] [Google Scholar]
  • 19. Bakris G, Gradman A, Reif M, Wofford M, Munger M, Harris S, Vendetti J, Michelson EL, Wang R, and the CLAIM Study Investigators : Antihypertensive efficacy of candesartan in comparison to losartan: The CLAIM study. J Clin Hypertens (Greenwich) 2001; 3 (1): 16–21 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES